JP2022505925A5 - - Google Patents

Info

Publication number
JP2022505925A5
JP2022505925A5 JP2021523011A JP2021523011A JP2022505925A5 JP 2022505925 A5 JP2022505925 A5 JP 2022505925A5 JP 2021523011 A JP2021523011 A JP 2021523011A JP 2021523011 A JP2021523011 A JP 2021523011A JP 2022505925 A5 JP2022505925 A5 JP 2022505925A5
Authority
JP
Japan
Prior art keywords
invention described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021523011A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022505925A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/059555 external-priority patent/WO2020093023A1/en
Publication of JP2022505925A publication Critical patent/JP2022505925A/ja
Publication of JP2022505925A5 publication Critical patent/JP2022505925A5/ja
Pending legal-status Critical Current

Links

JP2021523011A 2018-11-01 2019-11-01 抗tim-3抗体 Pending JP2022505925A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862754383P 2018-11-01 2018-11-01
US62/754,383 2018-11-01
PCT/US2019/059555 WO2020093023A1 (en) 2018-11-01 2019-11-01 Anti-tim-3 antibodies

Publications (2)

Publication Number Publication Date
JP2022505925A JP2022505925A (ja) 2022-01-14
JP2022505925A5 true JP2022505925A5 (cg-RX-API-DMAC7.html) 2022-11-08

Family

ID=69159931

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021523011A Pending JP2022505925A (ja) 2018-11-01 2019-11-01 抗tim-3抗体

Country Status (8)

Country Link
US (1) US20220081480A1 (cg-RX-API-DMAC7.html)
EP (1) EP3873611A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022505925A (cg-RX-API-DMAC7.html)
CN (1) CN113272017A (cg-RX-API-DMAC7.html)
AU (1) AU2019371457A1 (cg-RX-API-DMAC7.html)
CA (1) CA3117429A1 (cg-RX-API-DMAC7.html)
IL (1) IL282707A (cg-RX-API-DMAC7.html)
WO (1) WO2020093023A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7214440B2 (ja) * 2018-11-01 2023-01-30 三菱重工エンジニアリング株式会社 検証処理装置、検証処理方法及びプログラム
JPWO2023286854A1 (cg-RX-API-DMAC7.html) * 2021-07-16 2023-01-19
TW202327649A (zh) * 2021-09-15 2023-07-16 大陸商江蘇恆瑞醫藥股份有限公司 Pvrig/tigit結合蛋白聯合免疫檢查點抑制劑用於治療癌症
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
CN119654339A (zh) 2022-07-01 2025-03-18 特兰斯吉恩股份有限公司 包含表面活性蛋白-d和tnfsf成员的融合蛋白
WO2025202222A1 (en) 2024-03-25 2025-10-02 Institut National de la Santé et de la Recherche Médicale Therapeutic use of sting and tlrs agonists to induce p16 expression in immune cells
WO2026059950A1 (en) * 2024-09-10 2026-03-19 Agilent Technologies, Inc. Anti-human tim3 antibodies for in vitro diagnostics

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
DK1366067T3 (da) 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
US8993524B2 (en) 2010-03-05 2015-03-31 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
PL3099717T3 (pl) 2014-01-31 2019-10-31 Novartis Ag Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
HRP20210977T1 (hr) 2014-02-10 2021-09-17 Merck Patent Gmbh Ciljano inhibiranje tgf beta
AU2015340056A1 (en) * 2014-10-27 2017-05-25 Agency For Science, Technology And Research Anti-TIM-3 antibodies
US20180153986A1 (en) * 2015-04-24 2018-06-07 The Brigham And Women's Hospital, Inc. Interactions between ceacam and tim family members
US20180207273A1 (en) * 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
PT3370768T (pt) * 2015-11-03 2022-04-21 Janssen Biotech Inc Anticorpos que se ligam especificamente ao pd-1 e seus usos
US20190248893A1 (en) * 2016-07-14 2019-08-15 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
JOP20190013A1 (ar) * 2016-08-25 2019-01-31 Lilly Co Eli أجسام مضادة لـ (تي آي ام -3)
MA50677A (fr) * 2016-11-01 2021-07-14 Anaptysbio Inc Anticorps dirigés contre la protéine d'immunoglobuline de lymphocytes t et mucine 3 (tim-3)
TWI665216B (zh) * 2016-12-29 2019-07-11 財團法人生物技術開發中心 抗人類tim-3抗體及其使用方法
AU2018205401B2 (en) * 2017-01-09 2025-01-02 Tesaro, Inc. Methods of treating cancer with anti-TIM-3 antibodies
CN110050000B (zh) 2017-05-12 2022-07-26 苏州盛迪亚生物医药有限公司 含有TGF-β受体的融合蛋白及其医药用途

Similar Documents

Publication Publication Date Title
JP2023526975A5 (cg-RX-API-DMAC7.html)
JP2020040981A5 (cg-RX-API-DMAC7.html)
JP2020007340A5 (cg-RX-API-DMAC7.html)
JP2021151238A5 (cg-RX-API-DMAC7.html)
JP2021184963A5 (cg-RX-API-DMAC7.html)
JP2020534795A5 (cg-RX-API-DMAC7.html)
JPWO2020148954A5 (cg-RX-API-DMAC7.html)
JP2020042034A5 (cg-RX-API-DMAC7.html)
JP2021048879A5 (cg-RX-API-DMAC7.html)
JP2022122972A5 (cg-RX-API-DMAC7.html)
JP2022541332A5 (cg-RX-API-DMAC7.html)
JP2021518389A5 (cg-RX-API-DMAC7.html)
JP2022185040A5 (cg-RX-API-DMAC7.html)
JP2024026077A5 (cg-RX-API-DMAC7.html)
JP2019030304A5 (cg-RX-API-DMAC7.html)
JP2023514727A5 (cg-RX-API-DMAC7.html)
JP2017214405A5 (cg-RX-API-DMAC7.html)
JP2018154848A5 (cg-RX-API-DMAC7.html)
JP2023552816A5 (cg-RX-API-DMAC7.html)
JP2021100406A5 (cg-RX-API-DMAC7.html)
JP2023182571A5 (cg-RX-API-DMAC7.html)
JP2022064180A5 (cg-RX-API-DMAC7.html)
JP2021524864A5 (cg-RX-API-DMAC7.html)
JP2020079331A5 (cg-RX-API-DMAC7.html)
JP2023133317A5 (cg-RX-API-DMAC7.html)